DexCom, Inc. $DXCM Shares Purchased by Gradient Investments LLC

Gradient Investments LLC boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 8.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 291,663 shares of the medical device company’s stock after purchasing an additional 21,915 shares during the period. Gradient Investments LLC’s holdings in DexCom were worth $19,626,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DXCM. GAMMA Investing LLC boosted its position in shares of DexCom by 2.5% during the third quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock worth $474,000 after buying an additional 169 shares during the period. Praxis Investment Management Inc. lifted its stake in DexCom by 68.5% during the 3rd quarter. Praxis Investment Management Inc. now owns 10,461 shares of the medical device company’s stock worth $704,000 after acquiring an additional 4,251 shares in the last quarter. Corient Private Wealth LLC boosted its holdings in DexCom by 1.2% during the 2nd quarter. Corient Private Wealth LLC now owns 122,124 shares of the medical device company’s stock valued at $10,660,000 after acquiring an additional 1,433 shares during the period. Migdal Insurance & Financial Holdings Ltd. acquired a new position in DexCom in the 2nd quarter valued at about $45,000. Finally, Valeo Financial Advisors LLC increased its stake in DexCom by 26.1% during the second quarter. Valeo Financial Advisors LLC now owns 10,450 shares of the medical device company’s stock worth $912,000 after purchasing an additional 2,162 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

DexCom stock opened at $66.37 on Wednesday. The company has a current ratio of 1.56, a quick ratio of 1.38 and a debt-to-equity ratio of 0.45. The company has a fifty day simple moving average of $64.01 and a 200-day simple moving average of $74.09. The stock has a market cap of $25.89 billion, a P/E ratio of 36.87, a price-to-earnings-growth ratio of 1.41 and a beta of 1.51. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $93.25.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same quarter in the prior year, the company posted $0.45 earnings per share. DexCom’s revenue for the quarter was up 21.6% compared to the same quarter last year. Equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several recent research reports. Barclays set a $80.00 price objective on shares of DexCom and gave the company an “equal weight” rating in a research note on Monday, November 3rd. TD Cowen decreased their price target on shares of DexCom from $100.00 to $84.00 and set a “buy” rating for the company in a research report on Friday, October 31st. Truist Financial restated a “buy” rating and issued a $82.00 price target (down previously from $94.00) on shares of DexCom in a research note on Monday, November 3rd. Morgan Stanley upgraded DexCom from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $63.00 to $75.00 in a research note on Tuesday, December 2nd. Finally, Citigroup reissued a “buy” rating and set a $77.00 target price (up from $75.00) on shares of DexCom in a research note on Thursday, December 11th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $87.57.

Insider Transactions at DexCom

In other news, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total value of $58,766.84. Following the transaction, the director owned 27,031 shares in the company, valued at approximately $1,569,690.17. This represents a 3.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach bought 18,200 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The shares were acquired at an average price of $55.04 per share, with a total value of $1,001,728.00. Following the purchase, the chief operating officer owned 331,697 shares of the company’s stock, valued at $18,256,602.88. The trade was a 5.81% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders sold 7,866 shares of company stock valued at $448,177. 0.32% of the stock is currently owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.